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Commonly	used	abbreviations	
BNP:		 	 Brain-type	natriuretic	peptide	
BCIS-JS:		 British	Cardiovascular	Intervention	Society	jeopardy	score	
CABG:			 Coronary	artery	bypass	graft	surgery	
EF:		 	 Ejection	fraction	
HF:		 	 Heart	failure	
ICD:		 	 Implantable	cardioverter	defibrillator	
ICM:		 	 Ischemic	cardiomyopathy	
LV:		 	 Left	ventricular	
MRI:		 	 Magnetic	resonance	imaging	
MI:		 	 Myocardial	infarction	
OMT:		 	 Optimal	medical	therapy	
PCI:		 	 Percutaneous	coronary	intervention	
	
	
Condensed	Abstract	
Heart	failure	(HF)	due	to	coronary	artery	disease	is	associated	with	significant	
mortality	and	morbidity.	REVIVED-BCIS2	is	a	prospective,	multi-center,	open-
label,	randomized	controlled	trial	that	addresses	the	hypothesis	that	PCI	in	
combination	with	optimal	medical	therapy	(OMT)	will	reduce	all-cause	death	
and	hospitalization	for	HF	compared	to	a	strategy	of	OMT	alone	in	patients	with	
a	left	ventricular	ejection	fraction	(LVEF)	≤35%,	extensive	coronary	disease	and	
demonstrable	myocardial	viability.	Change	in	LVEF	is	a	major	secondary	
endpoint.	Follow-up	will	be	for	at	least	2	years	from	randomization.	400	of	700	
patients	have	been	enrolled	to	date.	
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Abstract	
	
Background:	Ischemic	cardiomyopathy	(ICM)	is	the	commonest	cause	of	heart	
failure	(HF)	and	is	associated	with	significant	mortality	and	morbidity.	Surgical	
revascularization	has	been	shown	to	improve	long-term	outcomes	in	some	
patients,	but	surgery	itself	carries	a	major	early	hazard.	Percutaneous	coronary	
intervention	(PCI)	may	allow	a	better	balance	between	risk	and	benefit.	
	
Objectives:	Evaluate	whether	PCI	in	combination	with	optimal	medical	therapy	
(OMT)	will	reduce	all-cause	death	and	hospitalization	for	HF	compared	to	a	
strategy	of	OMT	alone.	
	
Methods:	REVIVED-BCIS2	is	a	prospective,	multi-center,	open-	label,	
randomized	controlled	trial,	funded	by	the	National	Institute	for	Health	Research	
in	the	United	Kingdom.	Follow-up	will	be	for	at	least	2	years	from	randomization.	
Secondary	outcomes	include	left	ventricular	(LV)	ejection	fraction	(EF),	quality	
of	life	scores,	appropriate	Implantable	Cardioverter	Defibrillator	therapy	and	
acute	myocardial	infarction.	Patients	with	LVEF	≤35%,	extensive	coronary	
disease	and	demonstrable	myocardial	viability	are	eligible	for	inclusion	and	
those	with	a	myocardial	infarction	within	4	weeks,	decompensated	HF	or	
sustained	ventricular	arrhythmias	within	72	hours	are	excluded.	A	trial	of	700	
patients	has	more	than	85%	power	to	detect	a	30%	relative	reduction	in	hazard.		
	
Results:	400	patients	have	been	enrolled	to	date.	
	
Conclusion:	International	guidelines	do	not	provide	firm	recommendations	on	
the	role	of	PCI	in	managing	severe	ICM,	due	to	lack	of	robust	evidence.	REVIVED-	
BCIS2	will	provide	the	first	randomized	data	on	the	efficacy	and	safety	of	PCI	in	
ICM	and	has	the	potential	to	inform	guidelines	pertaining	to	both	
revascularization	and	HF.	
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Introduction	
The	prevalence	of	heart	failure	(HF)	due	to	left	ventricular	(LV)	systolic	
dysfunction	is	increasing	(1)	and	ischemic	cardiomyopathy	(ICM)	accounts	for	
approximately	60%	of	all	HF	cases(2,	3).	Pathophysiologically,	ICM	encompasses	
a	spectrum	of	sequelae	of	coronary	disease,	including	myocardial	infarction	(MI)	
(which	leads	to	irreversible	fibrosis)	and	hibernation	(a	potentially	reversible	
adaptation	to	repetitive	ischemia),	which	often	co-exist	in	a	given	patient	and	
can	both	lead	to	adverse	remodeling	and	LV	dysfunction.	Hibernation	was	a	term	
coined	nearly	40	years	ago	to	describe	the	reversal	of	remodeling	and	
augmentation	of	systolic	function	following	surgical	coronary	artery	bypass	
grafting	(CABG),	noted	in	patients	with	chronic	stable	angina	and	severe	LV	
dysfunction(4).	While	subsequent	observational	studies	of	surgical	
revascularization	appeared	to	confirm	the	existence	of	hibernation(5,	6),	until	
recently,	this	had	not	been	adequately	assessed	in	a	randomized	study.		
	
The	seminal	Surgical	Treatment	for	Ischemic	Heart	Failure	(STICH)	trial,	the	only	
randomized	evaluation	of	CABG	for	ICM	to	date,	enrolled	patients	with	a	LV	
ejection	fraction	(EF)	≤35%.		At	a	median	of	4.6	years,	the	primary	outcome,	all-
cause	mortality,	was	not	significantly	different	between	patients	treated	with	
optimal	medical	therapy	(OMT)	alone	compared	to	those	assigned	to	CABG	
surgery	(41%	vs.	36%,	hazard	ratio	(HR)	0.86,	95%	confidence	interval	(CI)	0.72	
to	1.04,	p=0.12)(7).	Mortality	in	the	first	30	days	was	significantly	higher	in	the	
surgical	group	(4%	vs.	1%,	HR	3.12,	95%	CI	1.33	–	7.32,	p=0.009).	This	finding	is	
in	keeping	with	the	known	association	between	mortality	and	LV	dysfunction	
following	CABG	surgery(8).	The	early	hazard	of	CABG	may	have	negated	the	
benefits	of	revascularization,	which	become	gradually	manifest	in	those	who	
survive	the	complications	of	surgery.	The	Surgical	Treatment	for	Ischemic	Heart	
Failure	Extension	Study	(STICHES)	reported	longer-term	mortality	data	from	the	
STICH	trial.		At	median	follow	up	of	approximately	10	years,	59%	of	patients	
assigned	to	CABG	died	versus	66%	in	the	medical	therapy	group	(HR	0.84;	95%	
CI	0.73-0.97;	p=0.02)(9).	Death	from	cardiovascular	causes	and	several	pre-
specified	composite	secondary	endpoints	also	occurred	less	often	in	the	CABG	
group.	The	critical	balance	between	safety	and	efficacy	is	also	borne	out	when	
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examining	the	impact	of	age	on	treatment	effect	in	STICH.	Long-term	survival	
benefit	was	most	apparent	in	the	youngest	patients	enrolled	in	the	trial	(in	
whom	the	risks	of	peri-procedural	mortality	and	morbidity	are	lowest)	and	this	
benefit	diminished	with	increasing	age(10).		
	
Given	the	lower	procedural	risks	associated	with	percutaneous	coronary	
intervention	(PCI),	it	has	the	potential	to	allow	the	benefits	of	revascularization	
to	be	realized	with	fewer	complications	than	CABG	surgery,	but	this	assertion	is	
yet	to	be	tested	in	a	randomized	trial.	Table	1	summarizes	randomized	and	
observational	studies	of	revascularization	versus	medical	therapy	published	in	
the	past	15	years	and	includes	the	proportion	of	patients	treated	by	PCI.	It	
should	be	noted	that	the	risk	of	longer-term	complications,	such	as	restenosis	
and	late	stent	thrombosis,	in	this	population	who	tend	to	have	complex	coronary	
disease	and	multiple	comorbidities,	is	largely	unknown.	While	numerous	
comparisons	have	been	made	between	PCI	and	CABG	in	patients	with	
symptomatic	coronary	disease,	most	of	the	large	randomised	trials	excluded	
patients	with	impaired	LV	function.	Less	than	2%	of	all	patients	included	in	the	
largest	randomised	controlled	trial	comparing	PCI	with	CABG,	SYNTAX,	had	
significant	LV	impairment	(EF<30%)	at	baseline(11).	We	reported	outcomes	of	
PCI	in	301	patients	with	severe	ICM	(mean	EF	24%),	showing	30-day,	6-month	
and	4	year	mortality	rates	of	1.3%,	6%	and	33%,	respectively(12,	13).	These	
results	appear	to	compare	favourably	with	the	surgical	data,	but	as	these	are	not	
matched	cohorts,	further	comparison	is	not	possible.	On	the	other	hand,	the	
degree	of	LV	impairment	is	a	known	determinant	of	adverse	outcome	even	in	
patients	undergoing	PCI(14)	and	whether	this	modality	of	revascularization	
would	offer	incremental	prognostic	benefit,	over	and	above	contemporary	HF	
medication	and	device	therapy,	is	unclear.	A	recent	meta-analysis	of	
observational	data	suggests	that	CABG	may	offer	superior	outcomes	compared	to	
PCI,	with	either	modality	being	preferable	to	medial	therapy	alone(15).	The	2014	
ESC	guidelines	for	revascularisation	make	a	class	IIb	recommendation	(with	a	
level	of	evidence	C)	for	PCI,	in	the	presence	of	viable	myocardium,	where	surgery	
is	not	indicated(16).		REVIVED-BCIS2	is	the	first	randomised	comparison	of	
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percutaneous	revascularisation	(with	OMT)	versus	OMT	alone	in	patients	with	
LV	dysfunction	and	viable	myocardium.	
	
Trial	hypotheses	and	outcome	measures	
The	principle	hypothesis	of	REVIVED_BCIS2	is	that	PCI	in	combination	with	OMT	
will	improve	event-free	survival	in	patients	with	ICM	and	viable	myocardium,	
compared	to	a	strategy	of	OMT	alone.	The	main	secondary	hypothesis	is	that	PCI	
will	improve	LV	systolic	function	in	this	cohort	compared	to	OMT	alone.	The	
primary	outcome	is	a	composite	endpoint	of	all-cause	death	or	hospitalization	
due	to	HF,	over	the	entire	duration	of	the	trial.	Patients	will	be	followed	up	for	at	
least	2	years	from	randomization	(expected	range	2	to	8.5	years).	The	major	
secondary	outcome	is	LVEF,	assessed	by	echocardiography,	6	and	12	months	
from	randomization.	Other	outcome	measures	include	cardiovascular	death,	all-
cause	death,	hospitalization	due	to	HF,	acute	MI,	appropriate	Implantable	
Cardioverter	Defibrillator	(ICD)	therapy,	quality	of	life	scores	(Kansas	City	
Cardiomyopathy	Questionnaire	and	EuroQol	EQ-5D-5L),	New	York	Heart	
Association	(NYHA)	functional	class,	unplanned	further	revascularization,	
Canadian	Cardiovascular	Society	(CCS)	angina	class,	health	resource	use,	serial	
Troponin	T	or	I	levels,	serial	Brain-type	Natriuretic	Peptide	(BNP	or	NT-proBNP)	
levels	and	the	incidence	of	major	bleeding.	Definitions	of	outcome	measures	are	
detailed	in	table	2.	
	
Study	Population	
Individuals	with	all	of	the	following	characteristics	will	be	eligible	for	inclusion:		
severe	LV	dysfunction	(EF≤35%),	extensive	coronary	disease	and	demonstrable	
viability	in	at	least	4	dysfunctional	myocardial	segments(17)	that	can	be	
revascularized	by	PCI.	As	this	is	a	trial	assessing	the	prognosis	of	patients	with	
LV	dysfunction,	those	with	a	spectrum	of	HF	symptoms	(NHYA	I	to	IV)	will	be	
enrolled.		
	
LVEF	is	assessed	by	the	biplane	Simpson’s	Rule/3D	echocardiography	or	by	
Magnetic	Resonance	Imaging	(MRI).	If	there	has	been	a	recent	clinical	diagnosis	
of	MI	(MI),	the	imaging	study	is	performed	at	least	4	weeks	after	the	MI.	
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Extensive	coronary	disease	is	defined	as	a	British	Cardiovascular	Intervention	
Society	myocardial	jeopardy	score	(BCIS-JS)(18)	of	at	least	6	(the	maximum	
possible	score	is	12;	a	calculation	tool	is	included	in	the	supplementary	
appendix).	The	BCIS-JS	can	be	applied	to	patients	with	or	without	previous	
bypass	grafts;	for	illustration,	patients	who	do	not	have	bypass	grafts	will	have	a	
BCIS-JS	≥6	if	they	have	significant	left	main,	proximal	LAD	or	at	least	proximal	
two-vessel	disease.	Myocardial	viability		is	characterized	using	the	AHA	17-
segment	model	and	can	be	assessed	using	any	recognised	modality,	including	
MRI,	Dobutamine	Stress	Echocardiography	(DSE),	Single	Photon	Emission	
Computerised	Tomography	(SPECT)	or	Positron	Emission	Tomography	(PET).	
	
Trial	exclusion	criteria	are	a	MI	within	4	weeks	of	randomization	(this	is	a	
clinical	definition	as	adjudicated	by	recruiting	centres);	acutely	decompensated	
HF	requiring	treatment	with	inotropes/	ventilation/MCS	within	72	hours	of	
randomization;	sustained	ventricular	tachycardia/fibrillation	(VT/VF)	or	
appropriate	ICD	discharges	within	72	hours	of	randomisation;	valve	disease	
deemed	by	the	local	heart	team	to	require	imminent	intervention;	any	
contraindications	to	PCI;	age	<18	yrs	(there	is	no	upper	age	limit);	estimated	
glomerular	filtration	rate	<	25	ml/min/1.73m2,	unless	established	on	dialysis;	
pregnancy;	previous	enrolment	in	REVIVED-BCIS2	or	current	enrolment	in	other	
trial	that	may	affect	REVIVED-BCIS2	outcome	data	and	life	expectancy	<	1	year	
due	to	non-cardiac	pathology.	
	
It	is	anticipated	that	some	eligible	candidates	(such	as	those	with	severe	limiting	
angina)	will	be	considered	for	revascularization	on	clinical	grounds,	at	the	
discretion	of	the	responsible	clinician	and	in	accordance	with	the	wishes	of	the	
patients.	Similarly,	in	some	cases,	eligible	patients	may	be	offered	coronary	
artery	bypass	surgery,	including	those	thought	to	benefit	from	adjunctive	
surgical	procedures	(like	valve	repair/replacement	or	left	ventricular	
reconstruction)	or	those	whose	coronary	anatomy	is	considered	by	the	local	
team	to	be	more	amenable	to	surgical	rather	than	percutaneous	
revascularization.		These	patients	will	not	be	enrolled	in	the	trial	but	the	
screening	log	(see	below)	will	capture	such	exclusions.	
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Trial	design,	conduct	and	organization	
REVIVED-BCIS2	is	a	prospective	randomized	controlled	trial,	conducted	across	
30-35	centers	in	the	United	Kingdom.	Once	the	principal	investigator	at	each	site	
confirms	the	eligibility	of	a	patient	and	written	informed	consent	is	obtained,	
randomization	is	carried	out	via	an	online	web-based	system.	Randomization	of	
the	treatment	assignment	is	stratified	by	center	using	randomly	permuted	
blocks	of	varying	size,	with	1:1	allocation	between	the	PCI	and	OMT	arms.	Given	
the	nature	of	PCI,	this	is	an	open-label	trial,	but	researchers	adjudicating	and	
analysing	trial	outcomes	will	be	blinded	to	treatment	assignment.	Figure	1	
summarizes	recruitment	and	study	flow.	
	
The	trial	is	sponsored	by	King’s	College	London,	UK	and	funded	by	the	UK	
Department	of	Health	via	the	National	Institute	for	Health	Research	(NIHR)	
(Health	Technology	Assessment	project	10/57/67)	with	oversight	by	a	Trial	
Steering	Committee	(TSC)	that	meets	pre-specified	independence	criteria	
(Figure	3).		A	Data	and	Safety	Monitoring	Committee	(DSMC)	has	been	convened	
and	a	DSMC	charter	developed,	which	includes	details	of	the	meeting	schedule	
and	stopping	guidelines.		The	DSMC	are	independent	of	the	trial	team	and	report	
directly	to	the	TSC.	The	Clinical	Trials	Unit	(CTU)	at	the	London	School	of	
Hygiene	and	Tropical	Medicine	coordinate	and	monitor	all	aspects	of	the	trial.	
The	trial	is	officially	endorsed	by	the	British	Cardiovascular	Intervention	Society	
(BCIS)	and	hence	is	referred	to	as	REVIVED-BCIS2.	
	
The	protocol	and	amendments	have	been	reviewed	and	approved	by	the	UK	
National	Research	Ethics	Service	(London	-	Westminster	committee;	REC	
reference	10/H0802/46).	The	trial	is	carried	out	in	accordance	with	the	
declaration	of	Helsinki	and	in	keeping	with	Good	Clinical	Practice	Guidelines.	
Registration	was	completed	before	recruitment	commenced	(NCT01920048)	
and	ISRCTN45979711).		The	first	patient	was	randomized	on	28th	August	2013	
and	at	the	time	of	this	publication,	400	patients	have	been	randomized.	Figure	2	
summarizes	the	study	timeline.	There	has	been	one	major	amendment	to	the	
protocol,	implemented	in	July	2014,	when	the	first	inclusion	criterion	was	
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modified	from	“LVEF	≤30%”	to	“LVEF≤35%”	to	facilitate	comparison	with	
relevant	literature	and	guidelines.	At	this	stage,	“≥CCS	class	3	angina”	was	
removed	from	the	list	of	exclusion	criteria,	due	to	the	difficulty	in	distinguishing	
angina	from	breathlessness	in	this	particular	population.	
	
Assessment	of	LV	function	and	viability	
Suitability	of	patients	on	the	basis	of	EF	will	be	adjudicated	by	the	participating	
centers,	on	the	basis	of	recent	echocardiography	or	MRI	studies.	All	patients	will	
also	have	echocardiography	performed	at	randomization	(if	the	qualifying	EF	
was	based	on	a	recent	echocardiogram,	this	can	be	submitted	as	the	baseline	
study)	as	well	as	6	and	12	months	later.	Baseline,	6	month	and	12	month	
echocardiograms	will	be	anonymized	and	submitted	to	an	independent	
echocardiography	core	laboratory	(at	Guy’s	and	St	Thomas’	Hospital,	London,	
UK),	which	will	determine	LV	volumes	and	EF	using	a	biplane	Simpson’s	method,	
for	evaluation	of	the	major	secondary	outcome.	The	core	laboratory	will	be	
blinded	to	treatment	assignment	as	well	as	to	the	timing	of	the	studies	in	relation	
to	randomization.	Core	laboratory	analysis	will	also	include	the	degree	of	mitral	
regurgitation	and	segmental	wall	motion.	
	
Myocardial	viability	testing	is	used	to	prospectively	predict	hibernation	by	
identifying	the	extent	of	fibrosis,	contractile	reserve,	membrane	integrity	or	
metabolic	activity(19).		There	has	never	been	a	randomized	evaluation	of	the	
value	of	viability	testing	in	the	management	of	ICM	and	observational	series	have	
reported	seemingly	conflicting	results.	A	meta-analysis	of	over	3000	patients	
with	ICM	from	24	studies	showed	that	mortality	was	lower	following	
revascularization	in	patients	with	viable	myocardium	but	that	this	benefit	was	
not	seen	in	the	absence	of	viability(20).	A	more	recent	observational	series	of	
patients	with	ICM	assessed	by	PET	showed	that	revascularization	was	associated	
with	lower	mortality	compared	to	OMT	when	the	extent	of	viability	exceeded	
more	than	10%	of	the	whole	myocardium(21).		However,	analysis	of	a	subgroup	
of	patients	in	the	STICH	trial	who	underwent	discretionary	viability	testing,	did	
not	demonstrate	an	interaction	between	the	response	to	revascularization	and	
their	viability	classification(22).	A	pertinent	consideration	is	the	fact	that	the	
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STICH	substudy	classified	patients	dichotomously	as	having	viable	hearts	or	not.	
However,	an	individual	with	ICM	usually	has	some	regions	that	are	clearly	viable	
and	others	that	are	not	and	with	PCI,	it	is	possible	to	target	revascularization	to	
myocardial	territories	selected	on	this	basis.	Notwithstanding	differences	in	
sensitivity	and	specificity	between	imaging	modalities,	in	order	to	ensure	
widespread	applicability	of	trial	results,	segmental	viability	will	be	determined	
by	any	recognized	modality	in	REVIVED.	Imaging	and	intervention	specialists	at	
each	participating	center	assess	segmental	viability	and	the	feasibility	of	
revascularizing	the	relevant	segments,	to	determine	whether	an	individual	
patient	will	be	eligible	for	randomization.		
	
Percutaneous	coronary	intervention	arm	
PCI	will	be	performed	according	to	local	protocols.	Dual	antiplatelet	therapy	
should	be	given	in	all	cases,	with	pre-loading,	and	the	post-PCI	duration	based	on	
the	individual’s	bleeding	risk	and	local/national	guidelines.	In	general,	drug-
eluting	stents	are	recommended,	but	in	patients	who	have	an	indication	for	long-
term	formal	anticoagulation	(e.g.	for	concurrent	atrial	fibrillation,	LV	thrombus	
or	venous	thromboembolic	disease),	the	choice	of	stent	type	should	be	based	on	
their	suitability	for	medium-term	combined	antiplatelet	and	anticoagulation	
therapy.		
	
Completeness	of	revascularization:	it	is	strongly	recommended	that	PCI	be	
attempted	on	all	significant	coronary	lesions	in	major	proximal	coronary	vessels	
(or	side	branches	>2.5mm	in	diameter)	subtending	viable	myocardium.	Lesion	
significance	is	defined	as	>70%	diameter	stenosis	on	angiography	or	for	lesions	
between	50	and	70%	diameter	stenosis,	when	accompanied	by	demonstrable	
reversible	ischemia	on	invasive	or	non-invasive	testing.		Planned	target	lesions	
will	need	to	be	identified	by	the	operator	and	recorded	by	the	trial	coordinator	
before	the	procedure.		Patients	who	meet	inclusion	criteria	and	have	chronic	
total	occlusion	(CTO)	of	coronary	arteries	subtending	viable	myocardial	
segments	should	be	considered	for	REVIVED,	provided	that	the	PCI	operators	
predict	a	high	likelihood	of	successfully	reopening	these	vessels.	It	is	
recommended	that	dedicated	CTO	operators,	in	units	that	have	this	degree	of	
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specialization,	undertake	such	cases.	The	coronary	disease	burden	at	baseline	
and	the	completeness	of	final	revascularization	will	be	characterized	by	the	
BCIS-JS	and	Revascularization	Index	(RI),	where	RI	=	(JSpre	–	JSpost)/JSpre(18).	The	
interaction	between	treatment	effect	and	RI	as	well	as	the	presence	of	a	CTO	will	
be	the	subject	of	a	separate	substudy.	
	
Staged	PCI:	a	single	stage	strategy	should	be	employed	where	possible.	However,	
provisional	staging	could	be	considered	in	patients	with	renal	dysfunction,	
complex	coronary	disease	(including	CTO)	or	if	it	is	felt	during	PCI	that	deferring	
intervention	to	one	or	more	vessels	is	in	the	patient’s	best	interests	(e.g.		due	to	
unexpected	high	contrast	volumes	or	procedural	complications	during	PCI	to	the	
first	vessel).	Staging	must	be	prespecified	at	the	index	procedure.	Urgent	
revascularization	before	the	planned	second	stage	procedure	will	be	considered	
a	secondary	endpoint.	
	
Optimal	medical	therapy	in	both	arms	
In	order	to	ensure	that	patients	in	both	arms	of	the	trial	receive	optimal	medical	
and	device	therapy,	there	is	a	nominated	heart	failure	lead	at	each	participating	
centre	who	is	actively	involved	in	patient	selection	and	monitoring	of	therapy	
during	the	course	of	the	trial.	Furthermore,	a	trial	Medical	Therapy	Committee	
has	been	established,	that	will	review	available	evidence	and	guidelines	at	least	
annually	and	refine	recommendations	to	ensure	that	drug	and	device	therapy	
given	to	all	patients	in	the	trial	remains	optimal	and	contemporary.	Each	site	is	
provided	with	a	standard	operating	procedure	for	delivering	and	monitoring	
OMT,	which	sets	out	classes	of	drugs	appropriate	for	trial	patients,	including	HF	
therapies	(such	as	angiotensin	converting	enzyme	inhibitor	or	angiotensin	
receptor	blocker	+/-	neprilysin	inhibitor,	betablocker	and	mineralocorticoid	
receptor	antagonist	(23))	and	secondary	prevention	for	atherosclerosis	
(including	statin	and	antiplatelet	agent)	as	well	as	recommended	treatment	
targets	(including	lipid	profile,	HbA1c,	resting	heart	rate).	Formal	
anticoagulation	for	LV	thrombus	detected	on	imaging	or	as	prophylaxis	for	
severe	LV	dysfunction/	dyskinesis	is	at	the	discretion	of	the	treating	physician.	
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Initiation	of	the	above	treatments,	dose-titration	and	relevant	monitoring	is	per	
local	HF	protocols.	
	
Eligible	patients	are	initiated	on	medical	therapy	prior	to	randomization	and,	in	
patients	presenting	with	de	novo	HF,	assessment	of	LV	EF	is	deferred	if	they	are	
not	on	appropriate	medical	therapy	at	presentation.	Optimization	of	medical	and	
device	therapy	will	continue	in	both	groups	even	after	randomization,	
throughout	the	course	of	the	trial.		
	
ICD	implantation	is	not	mandatory	for	inclusion	in	REVIVED,	although	many	
patients	who	fulfill	trial	eligibility	criteria	may	also	be	candidates	for	primary	
prevention	ICDs.	Participating	sites	are	encouraged	to	follow	international	
guidelines(23)		when	deciding	on	ICD	or	resynchronization	device	therapy	and	
to	make	and	document	the	decision	to	implant	(or	not	implant)	a	device,	before	
randomization.		
	
Statistical	considerations	
Power	Calculation:	In	the	STICH	trial,	the	rate	of	all	cause	death	or	hospitalization	
for	HF	at	5	years	was	54%	in	the	medical	therapy	group,	with	approximately	
50%	of	events	occurring	in	the	first	year	and	a	steady	rate	thereafter(7).	These	
data	are	similar	to	the	1	year	rates	of	death	or	HF	hospitalization	reported	in	
registries	of	Western	European	populations(24).	On	this	basis,	the	predicted	
occurrence	of	death	or	hospitalization	for	HF	at	two	years	is	36%	in	the	OMT	
group.	The	primary	outcome	will	be	measured	over	the	entire	trial	duration,	
with	a	minimum	follow-up	duration	of	two	years.	A	trial	of	700	(350	in	each	
group),	with	300	patients	experiencing	a	primary	outcome,	would	have	over	
85%	power	to	detect	a	hazard	ratio	of	0.7	(a	30%	relative	reduction	in	the	
hazard)	at	5%	significance,	allowing	for	up	to	5%	losses	by	the	end	of	follow-up.	
The	hazard	ratio	of	0.7	is	considered	clinically	meaningful	and	in	line	with	the	
magnitude	of	benefit	observed	across	other	treatment	modalities	in	this	
population.	For	the	major	secondary	endpoint,	even	half	this	sample	size	will	
provide	90%	power	to	detect	a	minimum	difference	in	EF	of	4%,	assuming	a	
standard	deviation	of	11%.		
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This	trial	will	be	a	comparison	of	initial	strategy,	rather	than	technique;	the	
projected	event	rates	and	hazard	ratio	allow	for	the	fact	that	OMT	patients	may	
undergo	subsequent	revascularization.	As	such,	no	additional	adjustments	have	
been	made	to	the	power	calculation	to	account	for	unplanned	revascularization	
in	the	OMT	arm.	In	patients	assigned	to	receive	OMT,	revascularization	by	PCI	or	
CABG	during	the	trial	would	only	be	recommended	in	one	of	the	following	
circumstances:	readmission	with	an	acute	coronary	syndrome	(diagnosed	on	the	
basis	of	typical	ischemic	symptoms	as	well	as	a	rise	in	cardiac	biomarker	levels	
or	dynamic	ST-segment	deviation	on	ECG),	deterioration	in	exertional	angina	to	
≥CCS	class	3	symptoms	or	the	occurrence	of	resistant	ventricular	arrhythmias	
considered	to	be	ischemic	in	etiology.		
	
Statistical	Analysis:	A	detailed	statistical	analysis	plan	will	be	finalized	before	any	
data	are	analyzed	by	treatment	assignment.	Analysis	of	outcomes	will	be	by	
treatment	assignment,	on	an	intention-to-treat	basis.	An	unadjusted	time-to-
event	analysis	will	be	performed	on	the	primary	outcome	using	data	across	all	
follow-up,	with	time	to	the	first	event	(or	censoring)	times	measured	from	
randomization.	Hazard	ratios	together	with	associated	confidence	intervals	will	
be	calculated	from	the	Cox	proportional	hazards	model.	Cumulative	event	rates	
will	be	calculated	and	presented	using	Kaplan-Meier	time-to-event	curves.	As	a	
measure	of	absolute	treatment	difference,	cumulative	event	rates	will	be	
compared	at	2	years.	Each	individual	component	of	the	primary	composite	
outcome	as	well	as	other	secondary	time	to	event	outcomes	will	be	analyzed	
using	the	above	methods.	Losses	to	follow-up	are	expected	to	be	minimal	and	
patients	will	be	included	up	until	the	time	they	experience	the	event	or	are	
censored.	Any	categorical	outcome	measures	compared	at	specific	time	points	
will	be	examined	using	risk	ratios	and	risk	differences,	confidence	intervals	and	
significance	tests.	Continuous	variables	will	be	analyzed	and	presented	as	mean	
treatment	differences,	confidence	intervals	and	p-values	derived	from	analysis	of	
co-variance	models	or	unpaired	t-tests	as	appropriate	(with	appropriate	
transformation	if	necessary).		
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Interim	analyses	by	treatment	assignment	are	not	planned.	A	limited	number	of	
subgroups	analyses	will	be	performed,	which	will	be	detailed	in	the	analysis	
plan.	A	risk	model	will	be	developed,	based	on	interactions	between	variables	
and	treatment	in	the	Cox	model,	and	used	to	examine	whether	the	impact	of	
treatment	depends	on	a	person’s	underlying	risk.		
	
Health	Economic	Analysis	
The	Centre	for	Health	Economics	at	the	University	of	York,	UK	will	perform	a	
formal	health	economic	analysis.	Data	will	be	collected	on	health	service	
resource	use	including	length	of	inpatient	stays,	outpatient	visits,	use	of	primary	
care	resources,	use	of	cardiovascular	medication	and	devices	and	subsequent	
cardiovascular	procedures.	Resource	use	will	be	valued	in	monetary	terms	using	
routine	unit	cost	data	relevant	to	the	UK	National	Health	Service	(NHS).		These	
will	include	NHS	Reference	Costs,	British	National	Formulary	drug	prices	and	the	
Personal	Social	Services	Research	Unit	(PSSRU)	survey	of	unit	costs.			
A	formal	cost	effectiveness	of	PCI	in	this	population	will	be	undertaken	using	a	
decision	analytic	framework,	which	will	be	a	cohort	model	with	states	
representing	death	and	different	levels	of	HF	symptoms.	Key	features	will	
include	the	quantification	of	health	benefits	in	terms	of	quality-adjusted	life	
years	(QALYs)	and	the	use	of	an	NHS	cost	perspective.	Standard	decision	rules	
will	be	used	to	assess	cost	effectiveness	and	extensive	sensitivity	analysis	will	be	
undertaken	(probabilistic	and	deterministic)	to	assess	the	implications	of	
uncertainty	in	the	available	evidence	for	cost-effectiveness.	Heterogeneity	in	cost	
effectiveness	between	different	sub-groups	of	patients	will	be	assessed	using	
methods	consistent	with	those	applied	to	clinical	outcomes.			
	
Data	Collection	and	Monitoring	
Each	patient’s	demographic	details,	medical	history,	electrocardiogram,	routine	
blood	results,	cardiac	medication,	LVEF,	viability	assessment,	ICD	interrogation	
result	(if	applicable)	and	the	BCIS-JS	are	recorded	at	baseline.	LVEF	will	be	
reassessed	at	6	and	12	months	as	detailed	above.	ICD	interrogation,	quality	of	
life	scores,	BNP	(or	NT-Pro	BNP)	level,	Troponin	(T	or	I)	level	and	cardiac	
medication	are	recorded	at	6,	12	and	24	months	post-randomization.	All	major	
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outcomes	and	Serious	Adverse	Events	are	collected	at	6,	12	and	24	months	for	all	
patients	and	yearly	thereafter	for	patients	who	have	been	randomized	more	than	
2	years	before	the	end	of	the	trial.	Additionally,	patients	who	undergo	
revascularization	(by	treatment	assignment	or	as	an	unplanned	procedure)	have	
Troponin	levels	checked	before	and	after	the	procedure.	Hospitalization	and	
mortality	will	be	tracked	using	national	databases	to	ensure	that	any	unreported	
major	outcome	events	are	identified.	The	DMSC	will	review	serious	adverse	
events	and	any	other	trial	safety	issues.	The	Clinical	Trial	Unit	collects	a	snapshot	
of	screening,	from	each	center,	twice	a	year.	Recruiting	centers	capture	details	of	
all	patients	with	extensive	CAD	and	EF	≤35%	during	this	representative	period.	
These	data	will	be	used	to	generate	a	Consort-style	flowchart,	describing	the	
total	population	screened	as	well	as	the	frequency	and	causes	of	patients	
excluded	from	the	trial.	
	
Conclusion	
Ischemic	cardiomyopathy	is	the	commonest	cause	of	HF	and	is	associated	with	
significant	mortality	and	morbidity.	Surgical	revascularization	has	recently	been	
shown	to	improve	long-term	outcomes	in	some	patients,	but	surgery	itself	
carries	a	major	early	hazard	in	this	group.	PCI	is	an	appealing	alternative	to	
surgery,	which	may	allow	a	better	balance	between	risk	and	benefit,	but	this	
assertion	has	never	been	formally	tested.	REVIVED	is	the	first	randomized	
controlled	trial	of	PCI	for	severe	ischemic	LV	dysfunction	and	will	provide	
important	data	that	will	inform	guidelines	on	revascularization	in	ICM.	
	 	
	 16	
References	
1.	Benjamin	EJ,	Blaha	MJ,	Chiuve	SE,	et	al.	Heart	Disease	and	Stroke	Statistics-
2017	Update:	A	Report	From	the	American	Heart	Association.	Circulation	
2017;135:e146–e603.	
2.	Gheorghiade	M,	Sopko	G,	De	Luca	L,	et	al.	Navigating	the	crossroads	of	
coronary	artery	disease	and	heart	failure.	Circulation	2006;114:1202–1213.	
3.	McMurray	JJV,	Packer	M,	Desai	AS,	et	al.	Angiotensin-neprilysin	inhibition	
versus	enalapril	in	heart	failure.	N.	Engl.	J.	Med.	2014;371:993–1004.	
4.	Rahimtoola	SH.	Coronary	bypass	surgery	for	chronic	angina--1981.	A	
perspective.	Circulation	1982;65:225–241.	
5.	Alderman	EL,	Fisher	LD,	Litwin	P,	et	al.	Results	of	coronary	artery	surgery	in	
patients	with	poor	left	ventricular	function	(CASS).	Circulation	1983;68:785–
795.	
6.	O'Connor	CM,	Velazquez	EJ,	Gardner	LH,	et	al.	Comparison	of	coronary	artery	
bypass	grafting	versus	medical	therapy	on	long-term	outcome	in	patients	with	
ischemic	cardiomyopathy	(a	25-year	experience	from	the	Duke	Cardiovascular	
Disease	Databank).	Am.	J.	Cardiol.	2002;90:101–107.	
7.	Velazquez	EJ,	Lee	KL,	Deja	MA,	et	al.	Coronary-artery	bypass	surgery	in	
patients	with	left	ventricular	dysfunction.	N.	Engl.	J.	Med.	2011;364:1607–1616.	
8.	Ståhle	E,	Bergström	R,	Edlund	B,	et	al.	Influence	of	left	ventricular	function	on	
survival	after	coronary	artery	bypass	grafting.	Ann.	Thorac.	Surg.	1997;64:437–
444.	
9.	Velazquez	EJ,	Lee	KL,	Jones	RH,	et	al.	Coronary-Artery	Bypass	Surgery	in	
Patients	with	Ischemic	Cardiomyopathy.	N.	Engl.	J.	Med.	2016;374:1511–1520.	
10.	Petrie	MC,	Jhund	PS,	She	L,	et	al.	Ten-Year	Outcomes	After	Coronary	Artery	
Bypass	Grafting	According	to	Age	in	Patients	With	Heart	Failure	and	Left	
Ventricular	Systolic	Dysfunction:	An	Analysis	of	the	Extended	Follow-Up	of	the	
STICH	Trial	(Surgical	Treatment	for	Ischemic	Heart	Failure).	Circulation	
2016;134:1314–1324.	
11.	Serruys	PW,	Morice	M-C,	Kappetein	AP,	et	al.	Percutaneous	coronary	
intervention	versus	coronary-artery	bypass	grafting	for	severe	coronary	artery	
disease.	N.	Engl.	J.	Med.	2009;360:961–972.	
12.	Perera	D,	Stables	R,	Thomas	M,	et	al.	Elective	intra-aortic	balloon	
counterpulsation	during	high-risk	percutaneous	coronary	intervention:	a	
randomized	controlled	trial.	JAMA	2010;304:867–874.	
13.	Perera	D,	Stables	R,	Clayton	T,	et	al.	Long-term	mortality	data	from	the	
balloon	pump-assisted	coronary	intervention	study	(BCIS-1):	a	randomized,	
controlled	trial	of	elective	balloon	counterpulsation	during	high-risk	
	 17	
percutaneous	coronary	intervention.	Circulation	2013;127:207–212.	
14.	Mamas	MA,	Anderson	SG,	O'Kane	PD,	et	al.	Impact	of	left	ventricular	function	
in	relation	to	procedural	outcomes	following	percutaneous	coronary	
intervention:	insights	from	the	British	Cardiovascular	Intervention	Society.	Eur.	
Heart	J.	2014;35:3004–12a.	
15.	Wolff	G,	Dimitroulis	D,	Andreotti	F,	et	al.	Survival	Benefits	of	Invasive	Versus	
Conservative	Strategies	in	Heart	Failure	in	Patients	With	Reduced	Ejection	
Fraction	and	Coronary	Artery	Disease:	A	Meta-Analysis.	Circ	Heart	Fail	
2017;10:e003255.	
16.	Authors/Task	Force	Members,	Windecker	S,	Kolh	P,	et	al.	2014	ESC/EACTS	
Guidelines	on	myocardial	revascularization:	The	Task	Force	on	Myocardial	
Revascularization	of	the	European	Society	of	Cardiology	(ESC)	and	the	European	
Association	for	Cardio-Thoracic	Surgery	(EACTS)Developed	with	the	special	
contribution	of	the	European	Association	of	Percutaneous	Cardiovascular	
Interventions	(EAPCI).	Eur.	Heart	J.	2014;35:2541–2619.	
17.	Cerqueira	MD,	Weissman	NJ,	Dilsizian	V,	et	al.	Standardized	myocardial	
segmentation	and	nomenclature	for	tomographic	imaging	of	the	heart.	A	
statement	for	healthcare	professionals	from	the	Cardiac	Imaging	Committee	of	
the	Council	on	Clinical	Cardiology	of	the	American	Heart	Association.	Circulation.	
2002	Jan	29;105(4):539-42.	
18.	De	Silva	K,	Morton	G,	Sicard	P,	et	al.	Prognostic	utility	of	BCIS	myocardial	
jeopardy	score	for	classification	of	coronary	disease	burden	and	completeness	of	
revascularization.	Am.	J.	Cardiol.	2013;111:172–177.	
19.	Schuster	A,	Morton	G,	Chiribiri	A,	Perera	D,	Vanoverschelde	J-L,	Nagel	E.	
Imaging	in	the	Management	of	Ischemic	Cardiomyopathy.	J.	Am.	Coll.	Cardiol.	
2012;59:359–370.	
20.	Allman	KC,	Shaw	LJ,	Hachamovitch	R,	Udelson	JE.	Myocardial	viability	testing	
and	impact	of	revascularization	on	prognosis	in	patients	with	coronary	artery	
disease	and	left	ventricular	dysfunction:	a	meta-analysis.	J.	Am.	Coll.	Cardiol.	
2002;39:1151–1158.	
21.	Ling	LF,	Marwick	TH,	Flores	DR,	et	al.	Identification	of	therapeutic	benefit	
from	revascularization	in	patients	with	left	ventricular	systolic	dysfunction:	
inducible	ischemia	versus	hibernating	myocardium.	Circ	Cardiovasc	Imaging	
2013;6:363–372.	
22.	Bonow	RO,	Maurer	G,	Lee	KL,	et	al.	Myocardial	viability	and	survival	in	
ischemic	left	ventricular	dysfunction.	N.	Engl.	J.	Med.	2011;364:1617–1625.	
23.	Ponikowski	P,	Voors	AA,	Anker	SD,	et	al.	2016	ESC	Guidelines	for	the	
diagnosis	and	treatment	of	acute	and	chronic	heart	failure:	The	Task	Force	for	
the	diagnosis	and	treatment	of	acute	and	chronic	heart	failure	of	the	European	
Society	of	Cardiology	(ESC)Developed	with	the	special	contribution	of	the	Heart	
Failure	Association	(HFA)	of	the	ESC.	Eur.	Heart	J.	2016;37:2129–2200.	
	 18	
24.	Maggioni	AP,	Dahlström	U,	Filippatos	G,	et	al.	EURObservational	Research	
Programme:	regional	differences	and	1-year	follow-up	results	of	the	Heart	
Failure	Pilot	Survey	(ESC-HF	Pilot).	Eur.	J.	Heart	Fail.	2013;15:808–817.	
25.	Gerber	BL,	Rousseau	MF,	Ahn	SA,	et	al.	Prognostic	value	of	myocardial	
viability	by	delayed-enhanced	magnetic	resonance	in	patients	with	coronary	
artery	disease	and	low	ejection	fraction:	impact	of	revascularization	therapy.	J.	
Am.	Coll.	Cardiol.	2012;59:825–835.	
26.	AlJaroudi	W,	Alraies	MC,	Hachamovitch	R,	et	al.	Association	of	left	ventricular	
mechanical	dyssynchrony	with	survival	benefit	from	revascularization:	a	study	
of	gated	positron	emission	tomography	in	patients	with	ischemic	LV	dysfunction	
and	narrow	QRS.	Eur.	J.	Nucl.	Med.	Mol.	Imaging	2012;39:1581–1591.	
27.	Velazquez	EJ,	Williams	JB,	Yow	E,	et	al.	Long-term	survival	of	patients	with	
ischemic	cardiomyopathy	treated	by	coronary	artery	bypass	grafting	versus	
medical	therapy.	Ann.	Thorac.	Surg.	2012;93:523–530.	
28.	Cleland	JGF,	Calvert	M,	Freemantle	N,	et	al.	The	Heart	Failure	
Revascularisation	Trial	(HEART).	Eur.	J.	Heart	Fail.	2011;13:227–233.	
29.	Sawada	SG,	Dasgupta	S,	Nguyen	J,	et	al.	Effect	of	revascularization	on	long-
term	survival	in	patients	with	ischemic	left	ventricular	dysfunction	and	a	wide	
range	of	viability.	Am.	J.	Cardiol.	2010;106:187–192.	
30.	Desideri	A,	Cortigiani	L,	Christen	AI,	et	al.	The	extent	of	perfusion-F18-
fluorodeoxyglucose	positron	emission	tomography	mismatch	determines	
mortality	in	medically	treated	patients	with	chronic	ischemic	left	ventricular	
dysfunction.	J.	Am.	Coll.	Cardiol.	2005;46:1264–1269.	
31.	Liao	L,	Cabell	CH,	Jollis	JG,	et	al.	Usefulness	of	myocardial	viability	or	ischemia	
in	predicting	long-term	survival	for	patients	with	severe	left	ventricular	
dysfunction	undergoing	revascularization.	Am.	J.	Cardiol.	2004;93:1275–1279.	
32.	Meluzín	J,	Cerný	J,	Spinarová	L,	et	al.	Prognosis	of	patients	with	chronic	
coronary	artery	disease	and	severe	left	ventricular	dysfunction.	The	importance	
of	myocardial	viability.	Eur.	J.	Heart	Fail.	2003;5:85–93.	
33.	Sicari	R,	Picano	E,	Cortigiani	L,	et	al.	Prognostic	value	of	myocardial	viability	
recognized	by	low-dose	dobutamine	echocardiography	in	chronic	ischemic	left	
ventricular	dysfunction.	Am.	J.	Cardiol.	2003;92:1263–1266.	
34.	Sawada	SG,	Lewis	SJ,	Foltz	J,	et	al.	Usefulness	of	rest	and	low-dose	
dobutamine	wall	motion	scores	in	predicting	survival	and	benefit	from	
revascularization	in	patients	with	ischemic	cardiomyopathy.	Am.	J.	Cardiol.	
2002;89:811–816.	
35.	Shah	BR,	Velazquez	E,	Shaw	LK,	Bart	B,	O'Connor	C,	Wagner	GS.	
Revascularization	improves	survival	in	ischemic	cardiomyopathy	regardless	of	
electrocardiographic	criteria	for	prior	small-to-medium	myocardial	infarcts.	Am.	
Heart	J.	2002;143:111–117.	
	 19	
36.	Thygesen	K,	Joint	ESC/ACCF/AHA/WHF	Task	Force	for	Universal	Definition	
of	Myocardial	Infarction,	Authors/Task	Force	Members	Chairpersons,	et	al.	Third	
universal	definition	of	myocardial	infarction.	J	Am	Coll	Cardiol.	
2012;60(16):1581-98.	
37.	Hicks	KA,	Tcheng	JE,	Bozkurt	B,	et	al.	2014	ACC/AHA	Key	Data	Elements	and	
Definitions	for	Cardiovascular	Endpoint	Events	in	Clinical	Trials:	A	Report	of	the	
American	College	of	Cardiology/American	Heart	Association	Task	Force	on	
Clinical	Data	Standards	(Writing	Committee	to	Develop	Cardiovascular	
Endpoints	Data	Standards).	J.	Am.	Coll.	Cardiol.	2015;66:403–469.	
38.	Mehran	R,	Rao	SV,	Bhatt	DL,	et	al.	Standardized	bleeding	definitions	for	
cardiovascular	clinical	trials:	a	consensus	report	from	the	Bleeding	Academic	
Research	Consortium.	J	Am	Heart	Assoc	2011;123:2736–47.	
	
	 	
	 20	
Figure	1:	STUDY	FLOW	
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Figure	2:	STUDY	TIMELINE	
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ends March 
2020 
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ends March 
2022 
Publication of 
results Q3 
2022 
No. of 
patients 
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1	 3	 10	 14	 19	 23	 26	 30	 30	 32	 32	 32	 32	 32	
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Figure	3:	Trial	Organization	
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Table	1.	Studies	of	revascularization	versus	medical	therapy	
published	between	2002	and	2017	
	
	
Follow-up	duration	is	quoted	as	mean	±	SD	or	median	(IQR).		
†	RCTs,	‡	adjusted	mortality/propensity	matched	data;	NR:	not	reported	
(6,	7,	9,	21,	25-35)	
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Table	2.	Definitions	of	outcome	measures	
	
Acute	Myocardial	
Infarction	(MI)	
	
	
	
	
1.	Spontaneous	MI	(≥48	hrs	after	PCI/CABG)		
Detection	of	a	rise	and/or	fall	of	cardiac	Troponin	T	or	I	levels,	
with	at	 least	one	value	higher	 than	 the	99th	 percentile	upper	
reference	 limit	 (URL)	 AND	 symptoms	 consistent	 with	
ischaemia	 OR	 dynamic	 ECG	 changes	 	 (including	 >1mm	 ST	
elevation,	 new	 Left	 Bundle	 Branch	 Block	 (LBBB)	 >1mm	 ST	
depression,	>3mm	T	wave	inversion)		
2.	Peri-procedural	MI	(<48	hrs	after	PCI/CABG)*	
Following	PCI,	Troponin	(T	or	I)	>	5	x	the	99th	percentile	URL)	
(or	 5	 x	 the	 baseline	 value	 if	 this	 is	 higher	 than	 the	 URL)	 in	
combination	with	any	of	(a)	evidence	of	prolonged	ischaemia	
(>20	min)	 as	 demonstrated	 by	 prolonged	 chest	 pain	 and/or	
ischaemic	ST	changes	or	(b)	new	pathological	Q	waves	or	(c)	
angiographic	evidence	of	a	flow	limiting	complication,	such	as	
of	loss	of	patency	of	a	side	branch,	persistent	slow-flow	or	no-
reflow,	 embolisation,	 or	 (d)	 imaging	 evidence	 of	 new	 loss	 of	
viable	myocardium	or	new	regional	wall	motion	abnormality.	
Following	CABG,	Troponin	(T	or	I)		>	10	x	99th	percentile	URL	
(or	 10	 x	 the	baseline	 value	 if	 this	 is	 higher	 than	 the	URL)	 in	
combination	with	any	of	the	following:	(i)	new	pathological	Q	
waves	or	 (ii)	 angiographically	documented	new	graft	or	new	
native	 coronary	 artery	 occlusion	 or	 (iii)	 imaging	 evidence	 of	
new	 loss	 of	 viable	myocardium	or	 new	 regional	wall	motion	
abnormality,	
3.	Sudden	death	
Cardiac	arrest	accompanied	by	new	ST	elevation/LBBB	on	ECG	
and/or	 evidence	 of	 fresh	 coronary	 thrombus	 at	
autopsy/angiography	
*	In	addition	to	classifying	patients	dichotomously,	as	having	suffered	
a	periprocedural	MI	or	not	on	the	basis	of	the	2012	Universal	Definition	
of	a	type	4	MI(36),	baseline	and	peak	Troponin	levels	measured	within	
24	hours	of	a	procedure	will	be	recorded.	This	will	provide	a	continuous	
outcome	measure	 of	 periprocedural	myocardial	 injury	 and	will	 also	
allow	 subsequent	 reclassification	 in	 the	 event	 of	 further	 revisions	 to	
definitions	of	periprocedural	MI	that	may	occur	during	the	course	of	
the	trial..	
Appropriate	ICD	
therapy	
At	least	one	ICD	shock	or	episode	of	anti-tachycardia	pacing	for	
documented	 ventricular	 tachycardia	 (VT)	 or	 ventricular	
fibrillation	(VF)		
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Cardiovascular	
death	
All	deaths	where	there	is	no	clinical	or	post-mortem	evidence	
of	a	non	cardiovascular	aetiology	
Hospitalization	
for	heart	failure	
(HF)(37).	
Hospital	admission	(lasting	at	least	24	hours)	for	deteriorating	
symptoms	 or	 signs	 of	 HF,	 where	 there	 is	 a	 documented	
diagnosis	 of	 HF	 and	 the	 patient	 receives	 initiation	 or	
intensification	of	treatment	for	HF.	Initiation	or	intensification	
of	treatment	includes	at	least	one	of	the	following:	increase	in	
oral	 diuretic	 dose	 or	 addition	 of	 another	 oral	 diuretic,	
intravenous	diuretic	 therapy,	 intravenous	 vasoactive	 therapy	
(vasodilator,	inotrope	or	vasopressor),	mechanical	circulatory	
support	 (MCS)	 (including	 intra-aortic	 balloon	pump,	 Impella,	
extra-corporeal	 membrane	 oxygenation)	 or	 cardiac	
transplantation.	
HF	during	or	after	the	assigned	PCI	procedure	itself	is	defined	
as	prolongation	of	the	planned	admission	by	at	least	24	hours	
due	to	acute	heart	failure	requiring	initiation	or	intensification	
of	 treatment	 as	 defined	 above.	 Prolongation	 of	 hospital	
admission	in	patients	who	have	prophylactic	pre-PCI	insertion	
of	a	MCS	should	not	be	recorded	as	having	a	HF	hospitalization	
unless	 there	 are	 features	 of	 HF	 requiring	 initiation	 or	
intensification	of	treatment	as	defined	above.	
Elective	admission	for	implantation	or	revision	of	ICD/cardiac	
resynchronization	therapy	(CRT)	devices	will	not	constitute	a	
HF	hospitalization	endpoint.		
Major	Bleeding	 Major	 bleeding	will	 be	 defined	 using	 the	 Bleeding	 Academic	
Research	Consortium	(BARC)	categories(38)	below:	
Type	3a		
¥! Overt	bleeding	plus	haemoglobin	drop	of	≥30	to	<50g/L	
(provided	haemoglobin	drop	is	related	to	bleed)	
¥! Any	transfusion	with	overt	bleeding	
	
Type	3b	
¥! Overt	 bleeding	 plus	 haemoglobin	 drop	 ≥50g/L	
(provided	haemoglobin	drop	is	related	to	bleed)	
¥! Cardiac	tamponade	
¥! Bleeding	 requiring	 surgical	 intervention	 for	 control	
(excluding	dental/nasal/skin/haemorrhoid)	
¥! Bleeding	requiring	intravenous	vasoactive	drugs	
	
Type	3c	
¥! Intracranial	 haemorrhage	 (does	 not	 include	
microbleeds	 or	 haemorrhagic	 transformation;	 does	
include	intraspinal)	
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¥! Subcategories;	 confirmed	 by	 autopsy	 or	 imaging	 or	
lumbar	puncture	
¥! Intra-ocular	bleed	compromising	vision	
	
Type	4:	CABG-related	bleeding	
¥! Perioperative	intracranial	bleeding	within	48	hours	
¥! Reoperation	 following	 closure	 of	 sternotomy	 for	 the	
purpose	of	controlling	bleeding	
¥! Transfusion	of	≥	5	units	of	whole	blood	or	packed	red	
blood	cells	within	a	48	period	
¥! Chest	tube	output	≥	2	L	within	a	24	h	period	
¥! If	a	CABG-related	bleed	is	not	adjudicated	as	at	 least	a	
Type	 3	 severity	 event,	 it	 will	 be	 classified	 as	 ‘not	 a	
bleeding	event’	
	
Type	5:	fatal	bleeding	
Type	5a	
¥! Probable	 fatal	 bleeding:	 no	 autopsy	 or	 imaging	
confirmation,	but	clinically	suspicious	
Type	5b	
¥! Definite	 fatal	 bleeding:	 overt	 bleeding	 or	 autopsy	 or	
imaging	confirmation	
	
Unplanned	
revascularisation	
PCI	 group:	 any	 unplanned	 target	 vessel	 or	 non-target	 vessel	
revascularisation	by	PCI	or	CABG	following	index	PCI,	excluding	
provisional	 staged	 PCI	 (with	 plan	 documented	 at	 the	 index	
procedure).		
OMT	group:	any	revascularisation	by	PCI	or	CABG	
	
	
		
	
